As Drug Discovery is embracing and utilizing Artificial Intelligence (AI) and Natural Language Programming (NLP) to advance the data analysis aspect of drug discovery, we are seeing more and more opportunities to improve and accelerate drug discovery and development more broadly.
Many bioanalytical scientists are currently pushing the boundaries to achieve an end to end solution in the regulated bioanalytical space by partnering 3D integrated robotics platforms (IRPs), robotic process automation (RPA), AI, NLP, common data framework, and effective system life cycle development to create an effective end to end solution for accelerating drug discovery and development. The AAPS Bioanalytical Community is embarking on establishing a subteam that will set the stage for how to implement, utilize, and get approval in regulated BA laboratories for these approaches.
If you are involved in utilizing these approaches in the bioanalytical space we invite you to join this subteam to discuss the opportunities, share your experience, and learn from others on the team.
We've already selected a leader to kick-off this team. Therefore, please send an email to Roy Helmy ( [email protected]) to join this discussion group.
------------------------------
Chad Briscoe PhD
VP of Global Bioanalytical Labs
Celerion
Lincoln NE
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------